These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 32235674)
1. A New Family of Iron(II)-Cyclopentadienyl Compounds Shows Strong Activity Against Colorectal and Triple Negative Breast Cancer Cells. Pilon A; Brás AR; Côrte-Real L; Avecilla F; Costa PJ; Preto A; Garcia MH; Valente A Molecules; 2020 Mar; 25(7):. PubMed ID: 32235674 [TBL] [Abstract][Full Text] [Related]
3. First iron(II) organometallic compound acting as ABCB1 inhibitor. Pilon A; Avecilla F; Mohai M; Enyedy ÉA; Rácz B; Spengler G; Garcia MH; Valente A Eur J Med Chem; 2023 Aug; 256():115466. PubMed ID: 37187089 [TBL] [Abstract][Full Text] [Related]
4. Cyclopentadienyl-ruthenium(II) and iron(II) organometallic compounds with carbohydrate derivative ligands as good colorectal anticancer agents. Florindo PR; Pereira DM; Borralho PM; Rodrigues CM; Piedade MF; Fernandes AC J Med Chem; 2015 May; 58(10):4339-47. PubMed ID: 25923600 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and antiproliferative activity of hydroxyferrocifen hybrids against triple-negative breast cancer cells. Cázares-Marinero Jde J; Top S; Vessières A; Jaouen G Dalton Trans; 2014 Jan; 43(2):817-30. PubMed ID: 24153445 [TBL] [Abstract][Full Text] [Related]
6. Novel ruthenium methylcyclopentadienyl complex bearing a bipyridine perfluorinated ligand shows strong activity towards colorectal cancer cells. Teixeira RG; Brás AR; Côrte-Real L; Tatikonda R; Sanches A; Robalo MP; Avecilla F; Moreira T; Garcia MH; Haukka M; Preto A; Valente A Eur J Med Chem; 2018 Jan; 143():503-514. PubMed ID: 29202411 [TBL] [Abstract][Full Text] [Related]
7. Synthesis, anticancer activity, and molecular docking of half-sandwich iron(II) cyclopentadienyl complexes with maleimide and phosphine or phosphite ligands. Das S; Strachanowska M; Wadowski P; Juszczak M; Tokarz P; Kosińska A; Palusiak M; Rybarczyk-Pirek AJ; Wzgarda-Raj K; Vasudevan S; Chworos A; Woźniak K; Rudolf B Sci Rep; 2024 Mar; 14(1):5634. PubMed ID: 38454122 [TBL] [Abstract][Full Text] [Related]
8. Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer. Zhao YQ; Yin YQ; Liu J; Wang GH; Huang J; Zhu LJ; Wang JH Acta Pharmacol Sin; 2016 Sep; 37(9):1237-50. PubMed ID: 27397540 [TBL] [Abstract][Full Text] [Related]
9. Efficient new constructs against triple negative breast cancer cells: synthesis and preliminary biological study of ferrocifen-SAHA hybrids and related species. Cázares Marinero Jde J; Lapierre M; Cavaillès V; Saint-Fort R; Vessières A; Top S; Jaouen G Dalton Trans; 2013 Nov; 42(43):15489-501. PubMed ID: 24030275 [TBL] [Abstract][Full Text] [Related]
10. Novel "ruthenium cyclopentadienyl"-peptide conjugate complexes against human FGFR(+) breast cancer. Franco Machado J; Machuqueiro M; Marques F; Robalo MP; Piedade MFM; Garcia MH; Correia JDG; Morais TS Dalton Trans; 2020 May; 49(18):5974-5987. PubMed ID: 32314752 [TBL] [Abstract][Full Text] [Related]
11. ONS-donor ligand based Pt(II) complexes display extremely high anticancer potency through autophagic cell death pathway. Rahman FU; Ali A; Duong HQ; Khan IU; Bhatti MZ; Li ZT; Wang H; Zhang DW Eur J Med Chem; 2019 Feb; 164():546-561. PubMed ID: 30622026 [TBL] [Abstract][Full Text] [Related]
15. Half-sandwich Os(ii) and Ru(ii) bathophenanthroline complexes: anticancer drug candidates with unusual potency and a cellular activity profile in highly invasive triple-negative breast cancer cells. Pracharova J; Novohradsky V; Kostrhunova H; Štarha P; Trávníček Z; Kasparkova J; Brabec V Dalton Trans; 2018 Sep; 47(35):12197-12208. PubMed ID: 30112527 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and docking studies of novel 4-aminophenol-1,2,4-oxadiazole hybrids as apoptosis inducers against triple negative breast cancer cells targeting MAP kinase. Dhanalakshmi B; Anil Kumar BM; Srinivasa Murthy V; Srinivasa SM; Vivek HK; Sennappan M; Rangappa S J Biomol Struct Dyn; 2024 Jul; 42(11):5841-5857. PubMed ID: 37529915 [TBL] [Abstract][Full Text] [Related]
17. The Curcumin Analog PAC Is a Potential Solution for the Treatment of Triple-Negative Breast Cancer by Modulating the Gene Expression of DNA Repair Pathways. Almalki E; Al-Amri A; Alrashed R; Al-Zharani M; Semlali A Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298600 [TBL] [Abstract][Full Text] [Related]